HIV nanomedicines

Developing a child-friendly treatment for HIV

Every day, a million children in sub-Saharan Africa are treated for HIV. Children as young as three weeks old get a twice-daily dose of antiretroviral drugs that has to be dissolved in strong alcohol.

Leading the world in HIV nanomedicines, we can change this.

Using Solid Drug Nanoparticle (SDN) technology, we are developing a child-friendly treatment for HIV, which can be dissolved in water not alcohol.

This new treatment also has the power to double the number of people treated from the same supply at the same cost – reducing costs for cash-strapped charities working on the ground.

What are nanomedicines?

1.8 million children have HIV in the world today, but there are no specific, optimisted therapies for children.

Professor Steve Rannard

The poorest countries need this new medicine the most. This is why we have chosen not to profit from its development. Instead, this medicine will be licensed for charitable use through our unique partnership with Medicine Patent Pool (MPP).

We want to get this new medicine into use as soon as possible. We have a product ready for manufacture and all pre-clinical trial data from our world-first trials of orally-dosed HIV nanomedicines. Our next steps are a manufacturing run and clinical trial, with a focus on paediatric nanomedicine.

We need your support to make this happen.

You can develop a child-friendly treatment for HIV by supporting us.